EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut microbiota functional profiling in autism spectrum disorders: bacterial VOCs and related metabolic pathways acting as disease biomarkers and predictors

Pamela Vernocchi, Chiara Marangelo, Silvia Guerrera, Federica Del Chierico, Valerio Guarrasi, Simone Gardini, Federica Conte, Paola Paci, Gianluca Ianiro, Antonio Gasbarrini, Stefano Vicari, Lorenza Putignani

Frontiers in Microbiology · 18.12.2023 · 14

DOI: 10.3389/fmicb.2023.1287350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 18.12.2023. Verfasst von Pamela Vernocchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder. Major interplays between the gastrointestinal (GI) tract and the central nervous system (CNS) seem to be driven by gut microbiota (GM). Herein, we provide a GM functional characterization, based on GM metabolomics, mapping of bacterial biochemical pathways, and anamnestic, clinical, and nutritional patient metadata.

Methods

Fecal samples collected from children with ASD and neurotypical children were analyzed by gas-chromatography mass spectrometry coupled with solid phase microextraction (GC–MS/SPME) to determine volatile organic compounds (VOCs) associated with the metataxonomic approach by 16S rRNA gene sequencing. Multivariate and univariate statistical analyses assessed differential VOC profiles and relationships with ASD anamnestic and clinical features for biomarker discovery. Multiple web-based and machine learning (ML) models identified metabolic predictors of disease and network analyses correlated GM ecological and metabolic patterns.

Results

The GM core volatilome for all ASD patients was characterized by a high concentration of 1-pentanol, 1-butanol, phenyl ethyl alcohol; benzeneacetaldehyde, octadecanal, tetradecanal; methyl isobutyl ketone, 2-hexanone, acetone; acetic, propanoic, 3-methyl-butanoic and 2-methyl-propanoic acids; indole and skatole; and o-cymene. Patients were stratified based on age, GI symptoms, and ASD severity symptoms. Disease risk prediction allowed us to associate butanoic acid with subjects older than 5 years, indole with the absence of GI symptoms and low disease severity, propanoic acid with the ASD risk group, and p-cymene with ASD symptoms, all based on the predictive CBCL-EXT scale. The HistGradientBoostingClassifier model classified ASD patients vs. CTRLs by an accuracy of 89%, based on methyl isobutyl ketone, benzeneacetaldehyde, phenyl ethyl alcohol, ethanol, butanoic acid, octadecane, acetic acid, skatole, and tetradecanal features. LogisticRegression models corroborated methyl isobutyl ketone, benzeneacetaldehyde, phenyl ethyl alcohol, skatole, and acetic acid as ASD predictors.

Conclusion

Our results will aid the development of advanced clinical decision support systems (CDSSs), assisted by ML models, for advanced ASD-personalized medicine, based on omics data integrated into electronic health/medical records. Furthermore, new ASD screening strategies based on GM-related predictors could be used to improve ASD risk assessment by uncovering novel ASD onset and risk predictors.

Schlagwörter

Stichwörter der Autor:innen

SCFAsautismclinical decision support system (CDSS) algorithmsgut microbiota volatilomemachine learningtryptophan-derived metabolism

Autor:innen und Institutionen

  • Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • GenomeUp, Rome, Italy.
  • Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy.
  • Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy.
  • CEMAD Digestive Disease Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Zitieren

APA

Vernocchi, P., Marangelo, C., Guerrera, S., Del Chierico, F., Guarrasi, V., Gardini, S., Conte, F., Paci, P., Ianiro, G., Gasbarrini, A., Vicari, S., & Putignani, L. (2023). Gut microbiota functional profiling in autism spectrum disorders: bacterial VOCs and related metabolic pathways acting as disease biomarkers and predictors. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1287350

Vancouver

Vernocchi P, Marangelo C, Guerrera S, Del Chierico F, Guarrasi V, Gardini S, et al. Gut microbiota functional profiling in autism spectrum disorders: bacterial VOCs and related metabolic pathways acting as disease biomarkers and predictors. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1287350

BibTeX
@article{Vernocchi2023,
  author = {Vernocchi, Pamela and Marangelo, Chiara and Guerrera, Silvia and Del Chierico, Federica and Guarrasi, Valerio and Gardini, Simone and Conte, Federica and Paci, Paola and Ianiro, Gianluca and Gasbarrini, Antonio and Vicari, Stefano and Putignani, Lorenza},
  title = {Gut microbiota functional profiling in autism spectrum disorders: bacterial VOCs and related metabolic pathways acting as disease biomarkers and predictors},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1287350}
}
Kostenlos starten →